METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
Baseline data from METRE-PL, the first placebo-controlled clinical study to evaluate the therapeutic efficacy and safety of metreleptin in familial partial lipodystrophy (FPLD), identified a substantial metabolic disease burden in this patient population, …